Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.
It is a hydrolytic lysosomal glucocerebroside-specific enzyme, a recombinant form of glucocerebrosidase.
Routes of administration-Intravenous
Elimination half-life-Plasma: 5–12 minutes and is absorbed by macrophages
The most common side effects include abdominal pain, headache, dizziness, bone pain, arthralgia#, back pain, infusion-related reactions, asthenia or fatigue and pyrexia.
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.
It is a hydrolytic lysosomal glucocerebroside-specific enzyme, a recombinant form of glucocerebrosidase.
Routes of administration-Intravenous
Elimination half-life-Plasma: 5–12 minutes and is absorbed by macrophages
The most common side effects include abdominal pain, headache, dizziness, bone pain, arthralgia#, back pain, infusion-related reactions, asthenia or fatigue and pyrexia.
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.